A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor Therapy

Inclusion criteria

• Age 18 years or older
• Pathologically confirmed diagnosis of breast cancer, colorectal cancer, head and neck squamous cell carcinoma, lung cancer, bladder cancer, gastric cancer, or pancreatic cancer
• Received antibody-based antitumor therapy at this center, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, or other antibody-based agents, either as monotherapy or combination therapy
• Completed at least one post-treatment efficacy assessment or had evaluable radiographic or clinical documentation of treatment response
• Available key clinical information, including demographics, tumor stage, line of therapy, treatment details, efficacy outcomes, or follow-up data
• Available data for at least one tumor microenvironment-related indicator, including tissue immunohistochemistry, molecular testing, or peripheral blood inflammatory markers

Exclusion criteria

• Missing key outcome information, including unevaluable treatment response or absence of follow-up or survival outcome records
• Missing key exposure information, including antibody-based therapy drug name or timing/line of therapy
• Concurrent active malignancy for which treatment outcomes cannot be clearly attributed to the cancer of interest
• Severely incomplete or unverifiable medical records
• Received only supportive or palliative care without exposure to antibody-based antitumor therapy